Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
City Of Hope National Medical Center · Fred Hutch Cancer Center · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
189
total citations
- FWCI
- 51.28
- Percentile
- 100%
- References
- 32
Citations per year
Authors
22Topics & keywords
Topics
Keywords
- Medicine
- Chronic lymphocytic leukemia
- Open label
- Lymphoma
- Oncology
- Internal medicine
- Leukemia
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- GSGilead Sciences
- CCelgene
- KTKaryopharm Therapeutics
- CBCSL Behring
- APActinium Pharmaceuticals
- TTTG Therapeutics
- NCNational Comprehensive Cancer Network
- SSunesis
- MPMEI Pharma
- ABAdaptive Biotechnologies
- BBeiGene
- IIncyte
- VOVerastem Oncology
- MModerna
- MMorphoSys
- GGenentech
- SOSchool of Medicine, Stanford University
- KPKite Pharma
- PPharmacyclics
- JTJuno Therapeutics
- LBLegend Biotech